Apogee Therapeutics (APGE) Common Equity (2022 - 2026)

Apogee Therapeutics (APGE) has 5 years of Common Equity data on file, last reported at $1.3 billion in Q1 2026.

• Quarterly Common Equity rose 86.5% year-over-year to $1.3 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 billion (up 86.5% YoY) and the FY2025 annual result came in at $903.9 million, up 26.1% from the prior year.
• Common Equity grew to $1.3 billion in Q1 2026 per APGE's latest filing, from $903.9 million in the prior quarter.
• Across five years, Common Equity topped out at $1.3 billion in Q1 2026 and bottomed at -$64.4 million in Q2 2023.
• The 5-year median for Common Equity is $602.9 million (2025), against an average of $480.0 million.
• The widest annual swing landed in 2023, when Common Equity sank 1353.08%; it then jumped 1818.32% in 2024.
• Tracing APGE's Common Equity over 5 years: stood at -$35.4 million in 2022, then jumped by 1173.44% to $379.9 million in 2023, then soared by 88.67% to $716.8 million in 2024, then increased by 26.1% to $903.9 million in 2025, then soared by 38.93% to $1.3 billion in 2026.
• Per Business Quant, the three latest APGE Common Equity figures stand at $1.3 billion (Q1 2026), $903.9 million (Q4 2025), and $586.3 million (Q3 2025).

Peer Comparison